Published in Cancer Control on February 24, 2003
Overestimation of carboplatin doses is avoided by radionuclide GFR measurement. Br J Cancer (2012) 0.77
Impact of Non-Pulmonary Visceral Metastases in the Prognosis and Practice of Metastatic Testicular Germ Cell Tumors. Oncol Rev (2016) 0.75
Successful treatment of disseminated extragonadal germ cell cancer with intensive conventional chemotherapy after first-line high-dose chemotherapy. Int J Clin Oncol (2006) 0.75
Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol (2011) 2.32
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial. J Natl Cancer Inst (2008) 2.07
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst (2008) 1.92
Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene (2003) 1.88
Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc Intervent Radiol (2008) 1.85
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol (2006) 1.66
Consensus conference on the management of tumor lysis syndrome. Haematologica (2008) 1.49
Developing clinical recommendations for breast, colorectal, and lung cancer adjuvant treatments using the GRADE system: a study from the Programma Ricerca e Innovazione Emilia Romagna Oncology Research Group. J Clin Oncol (2008) 1.46
Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor. Eur Urol (2006) 1.45
Germ cell tumours of the testis. Crit Rev Oncol Hematol (2005) 1.37
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. J Clin Oncol (2011) 1.31
Early nutritional intervention improves treatment tolerance and outcomes in head and neck cancer patients undergoing concurrent chemoradiotherapy. Support Care Cancer (2009) 1.23
Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer (2011) 1.19
Dose and outcome: the hurdle of neutropenia (Review). Oncol Rep (2006) 1.00
Nutritional intervention for improving treatment tolerance in cancer patients. Curr Opin Oncol (2011) 0.98
Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. Cancer (2005) 0.98
Risk evaluation, prophylaxis, and treatment of tumor lysis syndrome: consensus of an Italian expert panel. Adv Ther (2011) 0.98
Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nat Clin Pract Oncol (2008) 0.98
Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res (2005) 0.95
High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. Oncologist (2012) 0.93
Cost of insurance policies for investigator-initiated cancer clinical trials in Italy. Tumori (2005) 0.92
A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases. Gastric Cancer (2012) 0.90
Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead®, drug-eluting bead loaded with irinotecan: results of a phase II clinical study. Anticancer Res (2011) 0.89
Hepatic arterial chemotherapy with oxaliplatin, folinic acid and 5-fluorouracil in pre-treated patients with liver metastases from colorectal cancer. In Vivo (2007) 0.88
Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. J Clin Oncol (2002) 0.88
Capecitabine plus hepatic intra-arterial epirubicin and cisplatin in unresectable biliary cancer: a phase II study. Anticancer Res (2007) 0.88
Prevalence in the use of complementary medicine among cancer patients in Tuscany, Italy. Tumori (2008) 0.87
Congestive heart failure during imatinib mesylate treatment. Int J Cardiol (2009) 0.87
Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. Cancer (2005) 0.87
High-dose chemotherapy for germ cell tumors: do we have a model? Expert Opin Biol Ther (2014) 0.86
Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol (2008) 0.86
Decrease of CD4(+)FOXP3(+) T regulatory cells in the peripheral blood of human subjects undergoing a mental stressor. Psychoneuroendocrinology (2009) 0.85
Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings. Eur J Cancer (2008) 0.85
Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study. Melanoma Res (2003) 0.85
Prevention and therapy of neutropenia in elderly patients. Crit Rev Oncol Hematol (2003) 0.84
Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients. Expert Opin Biol Ther (2012) 0.84
High-dose chemotherapy for solid tumors: results of the EBMT. Crit Rev Oncol Hematol (2002) 0.83
Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma. Am J Surg (2002) 0.83
Allogeneic hematopoietic stem cell transplantation in ovarian cancer-the EBMT experience. Int J Cancer (2010) 0.83
Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years. In Vivo (2010) 0.83
Salvage high-dose chemotherapy in patients with germ cell tumors: an Italian experience with 84 patients. Cancer (2002) 0.83
Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice. Invest New Drugs (2011) 0.82
Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience. In Vivo (2009) 0.82
The status of high-dose chemotherapy with hematopoietic stem cell transplantation in germ cell tumor patients. Haematologica (2002) 0.82
Intra-arterial chemotherapy: a safe treatment for elderly patients with locally advanced breast cancer. In Vivo (2007) 0.82
Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report. Invest New Drugs (2010) 0.82
Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: results from the Italian observational "SUN" (Survey on the lUng cancer maNagement) study. Lung Cancer (2011) 0.82
Intra-arterial infusion of 5-fluorouracil, leucovorin, epirubicin and carboplatin (FLEC regimen) in unresectable pancreatic cancer: results of a ten-year experience. In Vivo (2007) 0.81
Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy. BMC Cancer (2014) 0.81
Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. Tumori (2012) 0.81
Expectations of survivors, caregivers and healthcare providers for testicular cancer survivorship and quality of life. Tumori (2011) 0.80
Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma. Cancer Chemother Pharmacol (2006) 0.80
What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta? Eur J Cancer (2009) 0.80
A high cytosol value of urokinase-type plasminogen activator (uPA) may be predictive of early relapse in primary breast cancer. Cancer Invest (2003) 0.80
Prognostic factors in patients with advanced pancreatic adenocarcinoma treated with intra-arterial chemotherapy. Pancreas (2008) 0.80
Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients. Melanoma Res (2009) 0.79
Clonal evolution at leukemic relapse of multiple myeloma (secondary plasma cell leukemia) responding to re-treatment with bortezomib-based therapy. A case record. Leuk Res (2009) 0.79
A new tool to enhance the efficacy of chemoembolization to treat primary and metastatic hepatic tumors. Expert Opin Drug Deliv (2011) 0.79
Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia. Cancer (2009) 0.79
Ovarian Sertoli-Leydig cell tumor, endometrioid-like yolk sac tumor, and Y-chromosomal material. Oncology (2003) 0.78
Selected hypoxic stop-flow perfusions: indication and limits. Tumori (2006) 0.78
IGG practice guidelines on germ cell tumor in adult male patients. Tumori (2008) 0.78
Does high-dose carmustine increase overall survival in supratentorial high-grade malignant glioma? An EBMT retrospective study. Int J Cancer (2007) 0.78
High-dose chemotherapy in small cell lung cancer. Tumori (2002) 0.77
High-dose chemotherapy with autologous hematopoietic stem cell support for solid tumors in adults. Semin Hematol (2007) 0.77
Use of granulocyte colony-stimulating factor: a survey among Italian medical oncologists. Oncol Rep (2005) 0.77
Sequential chemotherapy with cisplatin, leucovorin, and 5-fluorouracil followed by docetaxel in previously untreated patients with metastatic gastric cancer: a phase II study. Gastric Cancer (2012) 0.77
Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor? Biol Blood Marrow Transplant (2006) 0.77
Gemcitabine and paclitaxel combination as second-line chemotherapy in patients with small-cell lung cancer: a phase II study. Clin Lung Cancer (2012) 0.77
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). Lung Cancer (2010) 0.77
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study. Tumori (2015) 0.77
Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis. Breast Cancer Res Treat (2007) 0.77
Feasibility of radiotherapy after high-dose dense chemotherapy with epirubicin, preceded by dexrazoxane, and paclitaxel for patients with high-risk Stage II-III breast cancer. Int J Radiat Oncol Biol Phys (2006) 0.77
Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients. Tumori (2009) 0.77
Lack of activity of imatinib in two cases of KIT+ retroperitoneal liposarcoma. Hepatogastroenterology (2007) 0.77
Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: preliminary experience. Am J Clin Oncol (2004) 0.76
Germ cell tumors overexpress the candidate therapeutic target cyclin B1 independently of p53 function. Int J Biol Markers (2015) 0.76
Long-term outcome of salvage high-dose chemotherapy in patients with germ cell tumor with poor prognostic features. Urol Oncol (2009) 0.76
Creating real benefit for patients at risk of nausea and vomiting: palonosetron-from bench to bedside. Clin Adv Hematol Oncol (2007) 0.76
Targit for breast cancer. Tumori (2006) 0.75
Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer. Clin Colorectal Cancer (2010) 0.75
Germ-cell tumors. N Engl J Med (2007) 0.75
Progression-free survival in bevacizumab-based first-line treatment for patients with metastatic colorectal cancer: is it a really good end point? J Clin Oncol (2009) 0.75
Thyroid metastases from colorectal cancer: no longer a rare entity. Tumori (2006) 0.75